Edition:
United States

Senomyx Inc (SNMX.OQ)

SNMX.OQ on NASDAQ Stock Exchange Global Market

0.85USD
7 Dec 2016
Change (% chg)

-- (--)
Prev Close
$0.85
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
93,726
52-wk High
$4.85
52-wk Low
$0.91

Summary

Name Age Since Current Position

Kent Snyder

61 2014 Chairman of the Board

John Poyhonen

56 2014 President, Chief Executive Officer, Director

Antony Rogers

48 2012 Chief Financial Officer, Senior Vice President

Sharon Wicker

59 2009 Senior Vice President, Chief Commercial Development Officer

Jay Short

56 2008 Lead Independent Director

Daniel Stebbins

2015 Director

Stephen Block

70 2005 Independent Director

Mary Gray

63 2010 Independent Director

Michael Herman

73 2005 Independent Director

Christopher Twomey

55 2006 Independent Director

Biographies

Name Description

Kent Snyder

Mr. Kent Snyder is Chairman of the Board of Senomyx Inc. From June 2003 until January 2014 Mr. Snyder served as our Chief Executive Officer, and from June 2003 until September 2009 he served as our President. From July 1991 to October 2001, Mr. Snyder held various marketing and sales management positions with Agouron Pharmaceuticals, Inc., a Pfizer company. Mr. Snyder’s most recent position was President of Global Commercial Operations, and prior to that Mr. Snyder served as Senior Vice President of Commercial Affairs and Vice President of Business Development. Mr. Snyder is a former director of Santarus, Inc., a biopharmaceutical company that was acquired by Salix Pharmaceuticals, Ltd. in 2014. Mr. Snyder received his B.S. from the University of Kansas and his M.B.A. from Rockhurst College. Mr. Snyder contributes his extensive knowledge of the company and also ensures long-term continuity on the Board. In addition, he contributes operational and leadership skills that he has developed through his prior experience in various roles of increasing responsibility.

John Poyhonen

Mr. John W. Poyhonen has been appointed as President, Chief Executive Officer, Director of Senomyx Inc. Mr. Poyhonen joined us in October 2003 as Vice President and Chief Business Officer and was named Vice President, Chief Financial and Business Officer in April 2004. In January 2006, he was promoted to Senior Vice President, Chief Financial and Business Officer and in September 2009 he was promoted to President and Chief Operating Officer. From 1996 until October 2003, Mr. Poyhonen served in various sales and marketing positions for Agouron Pharmaceuticals, Inc., a Pfizer company, most recently as Vice President of National Sales and previously as Vice President of Marketing and Vice President of National Accounts. Mr. Poyhonen currently serves as a director of Heron Therapeutics, Inc., a specialty pharmaceutical company, and serves on that company’s Audit Committee and as the Chairman of its Compensation Committee. Mr. Poyhonen received his B.A. in Marketing from Michigan State University and his M.B.A. from the University of Kansas. Mr. Poyhonen contributes his extensive knowledge of the company. In addition, as a result of his long tenure with the company in roles of increasing responsibility, Mr. Poyhonen contributes his leadership skills and financial and operational expertise.

Antony Rogers

Mr. Antony E. Rogers is Chief Financial Officer, Senior Vice President of Senomyx Inc. Since joining Senomyx he has served in various roles of increasing responsibility and was appointed Vice President, Finance and Treasury in February 2006, Chief Financial Officer in September 2009, and he was promoted to his current position in January 2012. His previous experience includes various finance and accounting positions with Indiqu, Inc., Ancile Pharmaceuticals, Aurora Biosciences, and Sequana Therapeutics. Mr. Rogers received his B.S. in Accounting from San Diego State University.

Sharon Wicker

Ms. Sharon Wicker is Senior Vice President and Chief Commercial Development Officer of Senomyx Inc. From when Ms. Wicker joined Senomyx in April 2006 until September 2009 she served as our Senior Vice President of Commercial Development and Chief Strategy Officer. From 2003 to 2006, Ms. Wicker held various strategic marketing positions, most recently as President, Flavor Business Unit, at A.M. Todd Company. Prior to 2003 Ms. Wicker held various general management positions with Heinz, ConAgra and General Mills. Ms. Wicker received her B.S. in Food Science and Nutrition from Colorado State University and her M.B.A. from Michigan State University.

Jay Short

Dr. Jay M. Short, Ph.D., is Lead Independent Director of Senomyx Inc. Since March 2007, Dr. Short is a Co-founder of BioAtla, a protein therapeutics company based in San Diego and Beijing, where since 2007 he has served as Chairman and Chief Executive Officer. In addition, in August 2011 he transitioned to Chairman from Chief Executive Officer for Ciris Energy, a private company focused on natural gas and chemical generation from coal and biomass. Dr. Short also is Founder of the E.O. Wilson Biodiversity Foundation, a 501(c)(3) public charity, and served as its President and Chairman from its inception in October 2005 through July 2008. From February 1999 to October 2005, Dr. Short was the President and Chief Executive Officer of Diversa Corporation (acquired by BASF). Dr. Short received his Ph.D. in Biochemistry from Case Western Reserve University in Cleveland, Ohio and his B.A. with honors in Chemistry from Taylor University in Upland, Indiana. Dr. Short has also attended and received Director Certification from the UCLA Anderson School of Business. Dr. Short’s scientific expertise combined with his current and prior experience as a chief executive and a director of other publicly traded companies in the biotechnology industry make him particularly well suited for his role as the Board’s lead independent director and as a member of multiple Board committees.

Daniel Stebbins

Mr. Daniel Stebbins is Director of Senomyx, Inc. Mr. Stebbins has extensive leadership and commercial experience in the flavor and fragrance industry and has served on a number of industry association boards. Mr. Stebbins is currently the Non-Executive Chairman of Agilex Fragrances. He spent the majority of his career with Dragoco, including serving as President and CEO of Dragoco, North America , President of Dragoco Flavor Division, Worldwide, and a member of the Executive Board of Dragoco, GmbH. Mr. Stebbins was part of the executive team that merged Dragoco with Haarmann & Reimer (H&R), forming Symrise AG, the 4th largest flavor and fragrance company in the world. After such merger, Mr. Stebbins served as the President of the Symrise AG, Worldwide Flavor Division. He has been a leader on various industry association boards, serving as both a member and as President of the Flavor and Extract Manufacturers Association (FEMA) board of Governors and Fragrance Materials Association (FMA) board of Governors and as a member of the Research Institute for Fragrance Materials (RIFM) board of Governors and Fragrance Foundation board of Governors. Mr. Stebbins holds a Bachelor of Science degree from Castleton State College in Castleton, Vermont . Mr. Stebbins has been honored with numerous awards including the Erich Bruell award from the FMA and the International Fragrance Research Association (IFRA), as well as the Dr. Richard Hall award from FEMA for outstanding service to the fragrance and flavor industry.

Stephen Block

Mr. Stephen A. Block, Esq., is an Independent Director of Senomyx Inc., since March 2005. Mr. Block served as Chief Legal Officer and Secretary of International Flavors and Fragrances Inc., a leading creator, manufacturer and seller of flavors and fragrances (IFF), from January 1993 until his retirement in December 2003. He was named Senior Vice President, General Counsel and Secretary of IFF in February 2000. During his eleven years at IFF he also led the company’s Regulatory Affairs department. Prior to 1993, Mr. Block held various management positions, including Senior Vice President, General Counsel and Secretary, with GAF Corporation, a company specializing in specialty chemicals and building materials, and Celanese Corporation, a company specializing in synthetic fibers, chemicals and plastics. Mr. Block currently serves as an industry consultant, as a Managing Director of K5 Venture Partners, LLC, which manages an early stage venture fund and an accelerator/incubator, and as a member of the Executive Committee, Orange County Network, of the Tech Coast Angels, a leading angel investing group. Mr. Block is also a director of ChromaDex Corporation, a reference standards and ingredient supply company, and of several privately held companies. Mr. Block received his B.A. cum laude in Russian Studies from Yale University and his law degree from the Harvard Law School. Mr. Block’s background contributes to the Board’s understanding of the flavor industry.

Mary Gray

Dr. Mary Ann Gray, Ph.D., is an Independent Director of Senomyx Inc., since September 27, 2010. Since 2003 Dr. Gray has served as President of Gray Strategic Advisors, LLC, which provides strategic consulting services to the biotechnology industry. From 1999 to 2003, Dr. Gray was Senior Analyst and Portfolio Manager for the Federated Kaufmann Fund. Prior to 1999, Dr. Gray led biotechnology equity research groups at Raymond James & Associates, Warburg Dillon Read, and Kidder Peabody. Dr. Gray currently serves on the Boards of Directors of three other publicly traded biopharmaceutical companies, TetraLogic Pharmaceuticals, Dyax Corp. and Acadia Pharmaceuticals, Inc. At Dyax she serves as the lead independent director, Chair of the Compensation Committee and a member of the Nominating and Governance committee. At Acadia, she serves as Chairman of the Audit Committee and on the Compensation Committee. Dr. Gray holds a Ph.D. in pharmacology from the University of Vermont and a B.S. in biology from University of South Carolina. Dr. Gray brings to the Board her experience as a financial analyst and portfolio manager in the biotechnology industry, as well as a background in scientific research. In addition, through her past and current service as a director for other development stage biotechnology companies, Dr. Gray expands the Board’s exposure to corporate and board governance practices at peer companies. Carolina.

Michael Herman

Mr. Michael E. Herman is an Independent Director of Senomyx Inc., since May 2005. Mr. Herman has been serving as President of the Herman Family Trading Company. From January 1992 to December 2000, Mr. Herman was President of the Kansas City Royals Baseball Club. From January 1990 to December 1999, he was Chairman of the Finance and Investment Committee of the Kauffman Foundation and was its President from January 1985 to December 1990. From October 1974 to December 1990, Mr. Herman was the Executive Vice President and Chief Financial Officer of Marion Laboratories. Mr. Herman is a former director of Santarus, Inc., a biopharmaceutical company that was acquired by Salix Pharmaceuticals, Ltd. in 2014, and Cerner Corporation, a health care information technology company, and also is a Trustee of Rensselaer Polytechnic Institute, the University of Chicago Graduate School of Business and the Vail Valley Foundation. Mr. Herman holds a B.S. in metallurgical engineering from Rensselaer Polytechnic Institute and an M.B.A. from the University of Chicago. Through Mr. Herman’s prior business and financial experience, education and his service on other public company boards of directors he is able to provide operational expertise and leadership skills that are important to the Board, particularly in his capacity as Chairman of our Compensation Committee.

Christopher Twomey

Mr. Christopher J. Twomey is an Independent Director of Senomyx Inc., since March 2006. Mr. Twomey joined Biosite Incorporated, a medical diagnostics company, in March 1990 serving in various roles of increasing responsibility, and most recently serving as Senior Vice President, Finance and Chief Financial Officer until his retirement in 2007. At Biosite he was responsible for the Finance, Human Resources, Facilities, and Information Systems departments. From 1981 to 1990, Mr. Twomey worked for Ernst & Young LLP, where he served as an audit manager. Since August 2013 Mr. Twomey has served as a director and Chairman of the Audit Committee of Tandem Diabetes Care, Inc., a medical device company. Mr. Twomey is also a former director and Chairman of the Audit Committee of Cadence Pharmaceuticals, Inc., a specialty pharmaceutical company that was acquired by Mallinckrodt plc in 2014. Mr. Twomey holds a B.A. from the University of California at Santa Barbara. Mr. Twomey contributes substantial leadership skills and expertise in accounting and financial reporting that are especially valuable in his role as Chairman of our Audit Committee.

Basic Compensation

Options Compensation

Name Options Value

Kent Snyder

1,030,411 7,791,010

John Poyhonen

37,600 72,180

Antony Rogers

17,797 9,940

Sharon Wicker

100,464 641,671

Jay Short

0 0

Daniel Stebbins

0 0

Stephen Block

0 0

Mary Gray

0 0

Michael Herman

0 0

Christopher Twomey

0 0